HemOnc Today Current Issue

The following articles appeared in the print edition of HemOnc Today.

Table of Contents

• As oncology workforce ages, need for objective assessment of competency increases
• Should there be a mandatory retirement age for surgical oncologists?
• Cure and the shopping CAR T: Just pay millions at the cash register! Derek Raghavan, MD, PhD, FACP, FRACP, FASCO
• A team empowers a patient, and an empowered patient inspires the team S. Scott Balderson, PA-C
• ‘Window of opportunity’ exists for durvalumab as pancreatic cancer maintenance therapy
• More than 70% of childhood cancer survivors develop hypertension by age 50 years
• Immunotherapy provides ‘paradigm shift’ for treatment of head and neck cancer
• Hiking adventures raise money, awareness for multiple myeloma
• Atezolizumab plus chemotherapy improves PFS in non-small cell lung cancer
• Pembrolizumab reduces recurrence risk in stage III melanoma
• Nonchromosomal birth defects linked to higher risk for some childhood cancers
• Taselisib monotherapy appears active in PIK3CA-mutated solid tumors
• Neoadjuvant nivolumab induces pathologic responses in advanced resectable non-small cell lung cancer
• Socioeconomic factors, not race or ethnicity, linked to treatment refusal for advanced lung cancer
• Immunotherapy-chemotherapy combination extends survival in newly diagnosed metastatic lung cancer
• Biomarkers predict response to pembrolizumab in head and neck squamous cell carcinoma
• Dual IDO1, PD-L1 inhibition safe for advanced solid tumors
• American Association for Cancer Research presents special recognition awards
• Durvalumab-tremelimumab combination shows antitumor activity in urothelial cancer
• Prototype assays may facilitate development of blood tests for early cancer detection
• Analysis determines true cost for CAR T-cell therapy
• Postoperative chemotherapy offers no benefit in high-risk squamous cell head and neck carcinoma
• Gene transfer therapy leads to stable factor IX levels in hemophilia B
• Adherence to nutrition, physical activity guidelines reduces colon cancer mortality risk
• Low-fat meal enhances efficacy of reduced-dose abiraterone for prostate cancer
• Certain birth control methods may increase breast cancer risk
• Maintenance rituximab prolongs survival for certain patients with mantle cell lymphoma
• Hodgkin lymphoma survivors at increased risk for breast cancer
• Less intensive blood monitoring safe for chronic myeloid leukemia
• Ruxolitinib fails to improve outcomes for high-risk essential thrombocythemia
• Updated guidelines recommend palliative chemoradiotherapy for incurable non-small cell lung cancer
• Encorafenib plus binimetinib prolongs PFS in BRAF-mutated advanced melanoma
• FDA places partial clinical hold on tazemetostat trials
• FDA approves frontline Tagrisso for EGFR-mutant non-small cell lung cancer
• FDA grants fast track designation to balixafortide for metastatic breast cancer
• FDA grants priority review to Opdivo for small cell lung cancer
• FDA grants breakthrough therapy designation to Helimbra for hemophilia A without inhibitors
• FDA grants fast track designation to selinexor for penta-refractory myeloma
• FDA approves Tavalisse for chronic immune thrombocytopenia
• FDA approves Rubraca for recurrent ovarian cancer
• FDA grants priority review to dacomitinib for EGFR-positive non-small cell lung cancer
• FDA grants fast track designation to Gem-RIS for muscle-invasive bladder cancer
• FDA grants priority review to duvelisib for leukemia, lymphoma subtypes
• FDA expands approval of Vonvendi for von Willebrand disease
• FDA approves Opdivo-Yervoy combination for renal cell carcinoma
• Opioid prescriptions decline nearly 30% but remain ‘mainstay treatment’ for cancer-related pain
• Pediatric cancer specialists join NYU Langone
• Memorial Sloan Kettering names chief of computational oncology
• ASCO to present special awards
• Harvard hematologist receives children’s health research award
• CAR T-cell therapy pioneer among Time magazine’s 100 most influential people
• ATLAS trial of axitinib for renal cell carcinoma stopped due to futility
• Cyramza improves response in urothelial cancer
• First-line Keytruda improves survival for non-small cell lung cancer
• Trilaciclib reduces chemotherapy-induced myelosuppression in small cell lung cancer